Disposal

16 July 2007

                                Sale Of Hermal                                 

Reckitt Benckiser plc announces the conclusion of its strategic review of the
Hermal prescription skincare business, announced on 15th January 2007.

Reckitt Benckiser has agreed to sell Hermal to Laboratorios Almirall S.A., the
Spanish based international pharmaceutical company, for a consideration of £255
million in cash.

Hermal was acquired as part of the Boots Healthcare International (BHI)
business in January 2006. Hermal net revenues were £58m and operating profit
was £14m in 2006, representing approximately 1% of the net revenues and profits
of Reckitt Benckiser plc.

The disposal is subject to regulatory clearance in Germany and is expected to
complete during Q3 2007.

Reckitt Benckiser believes that the interests of the Hermal business and its
employees will be best served under the more appropriate ownership of an
international pharmaceutical company.

The Company has been advised by Goldman Sachs.

For Further Information

Tom Corran Reckitt Benckiser [phone]

Senior Vice President, Investor Relations & Corporate Communications

Fiona Fong Reckitt Benckiser [phone]

Head of Corporate Communications